International Journal of Hematology

, Volume 96, Issue 2, pp 247–253

Clinical characteristics of human immunodeficiency virus-associated Hodgkin lymphoma patients in Japan


    • Department of Laboratory MedicineTokyo Medical University
  • Shotaro Hagiwara
    • Division of HematologyNational Center for Global Health and Medicine
  • Atsushi Ajisawa
    • Division of Infectious DiseaseTokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital
  • Junko Tanuma
    • AIDS Clinical CenterNational Center for Global Health and Medicine
  • Tomoko Uehira
    • Department of Infectious DiseaseNational Hospital Organization Osaka National Hospital
  • Hirokazu Nagai
    • Department of HematologyNational Hospital Organization Nagoya Medical Center
  • Yuko Fujikawa
    • Division of Internal MedicineNagano Prefectural Foundation of Agricultural Cooperative for Health and Welfare, Saku Central Hospital
  • Shunichi Maeda
    • Division of ChemotherapyHachinohe City Hospital
  • Kiyoshi Kitano
    • Division of Internal MedicineMatsumoto Medical Center
  • Nobuyoshi Arima
    • Department of HematologyThe Tazuke Kofukai Medical Research Institute, Kitano Hospital
  • Kenji Uno
    • Center for Infectious DiseasesNara Medical University Hospital
  • Toshiki Iwai
    • Division of HematologyKyoto First Red Cross Hospital
  • Igen Hongo
    • Division of Infectious DiseaseMusashino Red Cross Hospital
  • Yasunori Ota
    • Division of PathologyToranomon Hospital
  • Katsuyuki Fukutake
    • Department of Laboratory MedicineTokyo Medical University
  • Seiji Okada
    • Center for AIDS ResearchKumamoto University
Original Article

DOI: 10.1007/s12185-012-1127-5

Cite this article as:
Yotsumoto, M., Hagiwara, S., Ajisawa, A. et al. Int J Hematol (2012) 96: 247. doi:10.1007/s12185-012-1127-5


The incidence of Hodgkin lymphoma (HL) is paradoxically increasing in the combination anti-retroviral therapy (cART) era. However, there has been no nationwide survey of human immunodeficiency virus (HIV)-associated HL (HIV-HL) in Japan. We retrospectively examined the clinical characteristics and outcomes of 19 newly diagnosed HIV-HL patients at 11 HIV/AIDS and hematology regional hospitals in Japan between 1991 and 2010. At the time of HL diagnosis, 79 % of patients were receiving cART. All the patients, but one received HL diagnoses in the cART era. The median CD4+ cell count at HIV-HL diagnosis was 169/μl. Mixed-cellularity classical Hodgkin lymphoma was the most common subtype occurring in 68 % of the patients; 89 % of the patients were positive for Epstein–Barr virus. Of these 19 patients, 84 % were in advanced stages, with bone marrow involvement observed in 47 % of the patients; 58 % had extranodal sites. All the treated patients were given cART concurrent with HL therapy. The complete remission rate of the treated patients was 87 %. The median OS of the entire cohort was 17 months. These results suggest that the characteristics of HIV-HL in Japan are more aggressive than those of non-HIV-associated HL in Japan, but standard chemotherapy is effective and feasible.


Hodgkin lymphomaHIV infectionABVDAntiretroviral therapyEBV

Copyright information

© The Japanese Society of Hematology 2012